HHS pledges $23M to develop Merck's experimental Ebola vaccine

In response to the Ebola outbreak in the Democtratic Republic of Congo, HHS will fund the development of Merck's investigational Ebola vaccine.

The department will give Merck $23 million to produce V920 doses over the next year and will work with the drugmaker to help secure FDA approval for the vaccine.